Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian OTC switch application inclusion of comparative label claims recommended in report.

This article was originally published in The Tan Sheet

Executive Summary

CANADIAN OTC SWITCH APPLICATION INCLUSION OF COMPARATIVE LABEL CLAIMS is suggested in a recent report on the Rx-to-OTC switch process issued for comment by the Canadian Drugs Directorate. The report, prepared for the directorate by Panacea Consulting Inc., recommends that the government's switch criteria "include submission of comparative therapeutic claims which will appear on the label, package and/or package insert" and that reviewers assess the information along with the rest of the submission.

Topics

UsernamePublicRestriction

Register

PS085414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel